,35 Although CH50 is often utilized in clinical practice to assess extent of complement inhibition with use of C5 inhibitors, the utility of CH50 and other complement assays to assess complement inhibition with pegcetacoplan, a C3 inhibitor, has not been established and requires further exploration.36, 37, 38 Overall, in this study, the findings of proteinuria reduction alongside increased serum C3 and reduced sC5b-9 provide evidence for clinically meaningful complement blockade in patients with C3G who are treated with pegcetacoplan. This evidence concerns the gene C5 and complement 3 glomerulopathy.